All data are based on the daily closing price as of March 28, 2025
s
SD BioSensor
137310.KO
6.45 USD
-0.18
-2.71%
Overview
Last close
6.45 usd
Market cap
772.05M usd
52 week high
11.14 usd
52 week low
5.60 usd
Target price
7.48 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
1.6309
Price/Book Value
0.3875
Enterprise Value
865.08M usd
EV/Revenue
1.8307
EV/EBITDA
0.1441
Key financials
Revenue TTM
472.54M usd
Gross Profit TTM
229.25M usd
EBITDA TTM
59.34M usd
Earnings per Share
N/A usd
Dividend
0.14 usd
Total assets
2.64B usd
Net debt
277.43M usd
About
SD Biosensor, Inc, an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company's products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters. The company was founded in 2010 and is headquartered in Suwon, South Korea.